SynthesisPloS one2026
The burden of Lipoprotein(a) [Lp(a)] in Africa: A systematic review.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipoprotein(a) [Lp(a)] is a low-density lipoprotein-like particle covalently bound to apolipoprotein(a) and encoded by the LPA gene. Elevated plasma levels of Lp(a) are a well-established, independent, and causal risk factor for cardiovascular disease. While the epidemiology of Lp(a) has been extensively mapped in non- African populations, the burden and distribution of Lp(a) in African populations remain under-characterized despite its unique genetic, phenotypic, ethnolinguistic and ancestral diversity. The primary objective was to synthesize existing literature to determine the prevalence and distribution of elevated Lp(a) levels in apparently healthy African individuals residing on the African continent.
methodsThis systematic review included observational studies (cross-sectional, cohort, and case-control) involving apparently healthy adults (≥18 years) in Africa. The review systematically searched PubMed/MEDLINE, Embase, Scopus, African Journals Online, and Google Scholar without language or date restrictions to capture the full breadth of historical and contemporary data. Data were extracted using a standardized form capturing study characteristics, population demographics, assay methods and quantitative outcomes. Methodological quality was assessed using the Newcastle-Ottawa Scale.
resultsA total of 17 studies met the inclusion criteria, representing populations from West Africa (Nigeria, Ghana) Central Africa (Cameroon), Southern Africa (South Africa, Zimbabwe), and North Africa (Morocco, Tunisia). Studies in Ghana reported prevalence rates of elevated Lp(a) (>30 mg/dL) between 30-61%. Lp(a) mean levels ranged from 12.7 mg/dL to 54.5 mg/dL depending on the cohort and assay used. Females exhibited higher Lp(a) levels than males across most African cohorts. Clinically, elevated Lp(a) was associated with hypertension, type 2 diabetes mellitus, ischemic stroke, myocardial infarction and anti-retroviral drug use.
conclusionElevated Lp(a) is a common, genetically determined trait in Africa rather than a rare dyslipidemia. Far from being a benign variant, it acts as a significant amplifier of cardiovascular risk, particularly in the presence of rising incident rates of hypertension and diabetes. Addressing this burden requires the adoption of standardized, isoform-independent assays and the development of population-specific risk thresholds to guide targeted preventive cardiovascular care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.